Will the CSL share price be heading higher from here?
The post Could it be time to consider buying CSL (ASX:CSL) shares? appeared first on The Motley Fool Australia. –
Since the start of the year, the biotherapeutics company’s shares are down 2% to $279.14.
Could it be time to consider buying CSL shares?
A number of Australia’s leading brokers have given their verdict on the CSL share price in recent months. And as you might expect due to COVID-19 uncertainties, opinion is largely divided on whether now is a good time to consider buying CSL shares.
Below is a summary of what brokers are saying about CSL shares in July 2021.
Citi currently has a neutral rating and $310.00 CSL share price target. This implies potential upside of 11% over the next 12 months. Citi is also forecasting a CSL dividend of $3.14 per share in FY 2021.
Goldman Sachs has a neutral rating and CSL share price target of $305.00. If CSL shares hit this level, it will mean a gain of 9.2%. In addition, Goldman has pencilled in a CSL dividend of $2.81 this year.
Morgans currently has an add rating and CSL share price target of $301.10. This represents a potential return of 7.9%. The broker is also forecasting a CSL dividend of $2.86 per share in FY 2021.
UBS is the most bullish broker with a buy rating and CSL share price target of $330.00. This implies potential upside of 18.2% over the next 12 months. UBS’ analysts are forecasting a CSL dividend of ~$2.33 per share in 2021.
The team at Goldman Sachs explained why they are neutral on the CSL share price.
Goldman said: “We are Neutral rated on CSL. Our 12-month TP of A$305 is based on our target NTM EV/EBITDA multiple of 28.9x. Key upside risks include: (1) Faster-than-expected recovery in plasma collections; (2) More supportive pricing dynamic than we already expect; (3) Positive results from the pipeline. Key downside risks include: (1) Extent of disruption to plasma collections; (2) Threat of mRNA/competitive approaches to Seqirus vaccine business; (3) Competitive product launches; (4) Plasma donor fee inflation.”
Should you invest $1,000 in CSL right now?
Before you consider CSL, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CSL wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of May 24th 2021
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.